Monday, December 11, 2017 - 15:01

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor events during the first quarter of 2018:

  • J.P. Morgan Annual Healthcare Conference – San Francisco, January 8-10, 2018
  • Oddo BHF Forum – Lyon, January 11-12, 2018
  • Innate Pharma R&D Day – London, March 8, 2018

 

*****

The Company will host an

R&D Day on March 8th, 2018,

in London, UK, from 1:00 to 5:00 pm GMT.

Innate Pharma’s management team will highlight Innate’s leading scientific role in immuno-oncology and its emerging proprietary portfolio, provide a more in-depth look at lead projects, IPH4102 and IPH5401, and their commercial potential.

The event is intended for institutional investors and sell-side analysts only. Please RSVP in advance if you plan to attend, as space is limited. To reserve a spot, please contact Consilium Strategic Communications, at InnatePharma@consilium-comms.com.

*****

 

Innate Pharma is committed to meet on a regular basis with the financial community. All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company’s website in the Investors’ section (www.innate-pharma.com/en/financials).

AttachmentSize
PR in English73.06 KB
CP en français74.65 KB